Effusive-constrictive pericarditis in the spotlight: Uncommon, often overlooked, and sometimes rever
"The report provides new information on the prevalence of effusive-constrictive pericarditis, its causation, clinical and hemodynamic features, natural history, and response to medical and surgical ...
Treatment with goflikicept, an anti-cytokine biologic, allows patients to discontinue other therapies for idiopathic recurrent pericarditis (IRP) and reduces the risk for recurrence compared with ...
Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- Colchicine may be as effective at reducing ...
Do DPP-4 Inhibitors Harm Patients with T2DM and Heart Failure? A review in Pharmacotherapy explores both contemporary pharmacotherapeutic therapies and emerging treatments and management strategies ...
DESCRIPTIONS of the syndrome of acute nonspecific or idiopathic pericarditis appearing since the report by Barnes and Burchell 1 have added little to knowledge of the subject. They have, however, ...
Did you know that bacteria and viruses can even attack your heart? Periarditis is one of the result of heart infection. Did you know that your heart can also get infected or inflamed? Yes, there are ...
LONDON--(BUSINESS WIRE)--The global pericarditis drugs market is expected to post a CAGR of more than 4% during the period 2019-2023, according to the latest market research report by Technavio. A key ...
DUBLIN--(BUSINESS WIRE)--The "Global Pericarditis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The pericarditis drugs market will register a CAGR of over 4% by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results